在以系统性红斑狼疮患者为对象的美国15家风湿科门诊中实施患者决策辅助工具的实施结局
本研究在美国15家风湿科门诊于2019年至2024年(含新冠疫情期间)实施一种有效的计算机化狼疮患者决策辅助工具,主要结局为渗透率(即查看过该工具的患者数占符合条件的患者总数)。15家门诊的渗透率在3%至44%之间,诊所内提供者总数与渗透率较高呈正相关;临床人员认为该工具在适宜性、可接受性、可行性、成功性和持久性方面表现良好,且在24个月内持续保持。
要点
- 15家美国风湿科门诊的狼疮患者决策辅助工具渗透率范围为3%至44%。
- 诊所内提供者总数与渗透率较高呈正相关。
- 临床人员在4个月时对该工具的适宜性、可接受性、可行性、成功性和持久性评分较优,且持续至24个月。
核心结论
- 在新冠疫情期间实施狼疮患者决策辅助工具取得了不同程度的成功,提供者数量较多的诊所渗透率较高;临床人员认为该工具具有较高的适宜性、可接受性、可行性、成功性和持久性,并持续至24个月。
研究设计与样本
- 研究于2019年至2024年(含新冠疫情期间)在美国15家风湿科门诊提供一种有效的计算机化狼疮患者决策辅助工具,并在基线开展组织变革准备度调查(ORIC)和团队学习与心理安全感调查(TLPSS)。
- 主要结局指标为渗透率(即研究结束时查看过狼疮患者决策辅助工具的患者数除以符合条件的患者总数,再乘以100)。
- 研究在实施后4个月、12个月和24个月使用经过验证的临床人员调查表评估对狼疮患者决策辅助工具适宜性、可接受性、可行性和成功性、持久性的感知。
- 参与调查的临床人员共n=184。
主要发现
- 15家地理分布多样的美国风湿科门诊的渗透率(主要结局)范围为3%至44%。
- 诊所内提供者总数与渗透率较高呈正相关。
- 基线ORIC承诺评分(0-5分,越高越好)范围为3.5至4.2,效能评分范围为3.4至4.4。
- 基线TLPSS评分(0-7分,越高越好):内部学习为3.9至5.5,外部学习为3.7至5.6,心理安全感为4.3至5.5。
- 临床人员感知的狼疮患者决策辅助工具结局在4个月时最佳(所有量表评分为1-5分,越高越好):适宜性3.43(标准差0.86)、可接受性3.53(标准差0.83)、可行性3.44(标准差0.71)、成功性3.41(标准差0.73)、持久性3.22(标准差0.74)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. METHODS: We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019-2024 (including the COVID pandemic). We undertook Organizational Readiness to Implement Change Surveys (ORICs) and Team Learning and Psychological Safety Surveys (TLPSSs) at baseline. The primary study outcome objective measure, percent penetration/reach, was defined as the number of patients who viewed the lupus PtDA at the end of the study, divided by the total number of eligible patients (times 100). We used validated clinical personnel surveys to examine the perceived lupus PtDA appropriateness, acceptability, feasibility, success, and permanence, at 4 months, 12 months and 24 months post-PtDA implementation. RESULTS: Among the sites, the clinical personnels' (n = 184) baseline ORIC commitment and efficacy scores (a 0-5 scale, higher = better) ranged from 3.5 to 4.2, and 3.4 to 4.4, respectively; the TLPSS scores (a 0-7 scale, higher = better) were 3.9-5.5 for internal learning, 3.7-5.6 for external learning, and 4.3-5.5 for psychological safety. The penetration (primary outcome) among 15 geographically diverse US rheumatology clinics ranged from 3% to 44%. We found that the total number of providers in the clinic was positively associated with higher penetration. Clinical personnel-perceived lupus PtDA outcomes were optimal at 4 months (all scale scores ranged from 1 to 5, higher = better): (i) appropriateness, 3.43 (s.d. 0.86); (ii) acceptability, 3.53 (s.d. 0.83); (iii) feasibility, 3.44 (s.d. 0.71); (iv) success, 3.41 (s.d. 0.73); and (v) permanence, 3.22 (s.d. 0.74). CONCLUSION: We implemented a lupus PtDA with varied success rates during the COVID pandemic; more providers were associated with higher clinic penetration. Clinical personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24 months. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03735238.
引用
- Singh JA, Hearld LR, Eisen S, et al. Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics. Rheumatology (Oxford). 2025. PMID: 40221856. doi:10.1093/rheumatology/keaf205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。